 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Alnylam ATTR Program on Track as Company Explores Subcutaneous Delivery for Cholesterol Drug
November 08, 2012
Alnylam ATTR Program on Track as Company Explores Subcutaneous Delivery for Cholesterol Drug
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Finds Partner for Cholesterol Program in The Medicines Company
February 7, 2013 / Gene Silencing News - Alnylam Adds New Program to Pipeline as It Shelves Anemia Candidate
January 10, 2013 / Gene Silencing News - With Alnylam Settlement Money in Hand, Tekmira Plans 'Aggressive' Pipeline Advancement
November 15, 2012 / Gene Silencing News - Alnylam Steps Back from Huntington's Drug Deal, Sees Two Partnerships by Year-End
May 10, 2012 / Gene Silencing News - Alnylam Focuses on Two Lead Programs, Won't Advance Others without Partners
January 12, 2012 / Gene Silencing News